Plasma IFNL3 for Gastric Cancer Detection and Monitoring in East Asians: A Multiphase Study
Cancer Medicine · 2026-11 · 15 (11)
DOI: 10.1002/cam4.72381 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 03.11.2026. Verfasst von Yunmeng Nie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Interleukins, Stomach Neoplasms. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Key Project of the Joint Fund for Regional Innovation and Development of the National Natural Science Foundation of China, Natural Science Foundation of Hangzhou, Research Project of Zhejiang Chinese Medical University.
Abstract (Originalsprache)
Background
Gastric cancer (GC) has a high incidence in East Asia, yet early detection remains limited.
Methods
In this multiphase study, 395 participants (96 GC, 72 precancerous lesions, 227 healthy donors) were enrolled. Plasma IFNL3 levels were measured using ELISA. Mendelian randomization was used to assess the causality between IFNL3 and GC. Receiver operating characteristic curves were used to calculate diagnostic efficiency in comparison between IFNL3 and traditional biomarkers (alpha fetoprotein [AFP], carcinoembryonic antigen [CEA], and cancer antigen 19‐9 [CA19‐9]).
Results
Bidirectional Mendelian randomization analysis suggested a potential association between plasma IFNL3 and GC in East Asians. In Test phase, plasma IFNL3 demonstrated superior diagnostic performance in differentiating GC from HDs (AUC = 0.901, 95% CI: 0.866–0.935) compared to AFP, CEA, and CA19‐9. IFNL3 levels correlated with disease progression, increasing progressively across clinical stages. IFNL3 mRNA was also higher in cancerous tissues compared to normal and para‐cancerous tissues. In Validation phase, IFNL3 exhibited high diagnostic specificity. In Extension phase, plasma IFNL3 showed distinct diagnostic potential for differentiating chronic non‐atrophic gastritis (CNAG), atrophic intestinal metaplasia (AIM), low‐grade intraepithelial neoplasia (LGIN), and high‐grade intraepithelial neoplasia (HGIN).
Conclusions
Plasma IFNL3 levels were increased in gastric cancer and correlated with disease progression. However, its value as a diagnostic biomarker requires validation in larger, stage‐adjusted studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
- Key Laboratory of Traditional Chinese Medicine for the Treatment of Intestine-Liver of Zhejiang Province, Hangzhou, People's Republic of China.
- School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
- Zhejiang Key Laboratory of Blood-Stasis-Toxin Syndrome, Hangzhou, People's Republic of China.
ORCID-Profile: Yunmeng Nie, Yingchao Liu, Shuo Zhang, Guangji Zhang
Förderung
- Key Project of the Joint Fund for Regional Innovation and Development of the National Natural Science Foundation of China
- Natural Science Foundation of Hangzhou
- Research Project of Zhejiang Chinese Medical University
Zitieren
APA
Nie, Y., Zhong, J., Ni, S., Liu, Y., Zhang, S., & Zhang, G. (2026). Plasma IFNL3 for Gastric Cancer Detection and Monitoring in East Asians: A Multiphase Study. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72381
Vancouver
Nie Y, Zhong J, Ni S, Liu Y, Zhang S, Zhang G. Plasma IFNL3 for Gastric Cancer Detection and Monitoring in East Asians: A Multiphase Study. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72381
BibTeX
@article{Nie2026,
author = {Nie, Yunmeng and Zhong, Jihong and Ni, Siyi and Liu, Yingchao and Zhang, Shuo and Zhang, Guangji},
title = {Plasma IFNL3 for Gastric Cancer Detection and Monitoring in East Asians: A Multiphase Study},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/cam4.72381}
}
EUVIMED